Nomegestrol acetate
 |
|
| Clinical data | |
|---|---|
| Trade names | Alone: Lutenyl With E2: Naemis, Zoely |
| Routes of administration |
Oral, subdermal implant |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 63% |
| Protein binding | 97.5–98% (to albumin) |
| Metabolism | Hepatic (via hydroxylation by CYP3A3, CYP3A4, CYP2A6) |
| Metabolites | Six main metabolites, all essentially inactive |
| Biological half-life | ~50 hours (range 30–80 hours) |
| Excretion | Urine, feces |
| Identifiers | |
|
|
| Synonyms | NOMAC; NOMAc; TX-066; Uniplant; 19-Normegestrol acetate; 6-Methyl-17α-acetoxy-6-19-norprogesterone |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ECHA InfoCard | 100.055.781 |
| Chemical and physical data | |
| Formula | C23H30O4 |
| Molar mass | 370.4819 g/mol |
| 3D model (Jmol) | |
|
|
|
|
Nomegestrol acetate, abbreviated as NOMAC, is a progestin, or a synthetic progestogen, which was first introduced in the mid-1980s and is used in the treatment of gynecological disorders, in hormone replacement therapy (HRT) for menopausal symptoms, and in hormonal contraceptives. It is marketed alone under the brand name Lutenyl and in combination with estradiol under the brand names Naemis and Zoely. NOMAC is widely available in Europe and in many countries throughout the world, though it is notably not available in the United States.
NOMAC is used alone (as Lutenyl) or in combination with estradiol (as Naemis) for the treatment of menstrual disturbances (e.g., dysmenorrhea, menorrhagia) and premenstrual syndrome and as a component of HRT for menopause. It is also used as an oral contraceptive with estradiol (as Zoely).
Because NOMAC is metabolized by the liver, hepatic impairment can result in an accumulation of the drug.
Side effects of NOMAC are infrequent and may include abnormal withdrawal bleeding (usually shorter, lighter, or absent menstruations), headache, and weight gain.
...
Wikipedia